These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1251772)

  • 41. Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration.
    Pollick C; Kimball B; Henderson M; Wigle ED
    Am J Cardiol; 1988 Dec; 62(17):1248-51. PubMed ID: 3195486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias.
    Nakamura M; Xue Y; Eto K; Hashimoto K
    J Cardiovasc Pharmacol; 1996 Mar; 27(3):368-75. PubMed ID: 8907798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of combined administration of verapamil and disopyramide in dogs.
    Lee JT; Davy JM; Kates RE
    J Cardiovasc Pharmacol; 1985; 7(3):501-7. PubMed ID: 2410681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Hemodynamic effects of disopyramide on postischemic and normal myocardium].
    Hoffmeister HM; Hörmann HP; Beyer M; Seipel L
    Klin Wochenschr; 1990 Dec; 68(23):1178-82. PubMed ID: 2280581
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The antiarrhythmic effect of intravenous disopyramide in an open study.
    Tonkin AM; Heddle WF; Bett JH; Kemp RJ; Donnelly GL; Nelson GI; Manolas E; Sloman JG
    Aust N Z J Med; 1982 Aug; 12(4):271-5. PubMed ID: 6958238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular pharmacology of quazodine (MJ-1988), with particular reference to effects of myocardial blood flow and metabolic heat production.
    Parratt JR; Winslow E
    Br J Pharmacol; 1971 Jun; 42(2):193-204. PubMed ID: 4397441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Intravenously disopyramide phosphate administration for treatment of arrhythmias].
    Aquaro G; Belli R; Pavia M; Rey L; Ravera A; Possavino G; Idone P
    G Ital Cardiol; 1982; 12(7):509-19. PubMed ID: 7169147
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemodynamic effects of intravenous butopamine in congestive heart failure.
    Thompson MJ; Huss P; Unverferth DV; Fasola A; Leier CV
    Clin Pharmacol Ther; 1980 Sep; 28(3):324-34. PubMed ID: 7408391
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of intravenous verapamil on hemodynamics in patients with heart disease.
    Singh BN; Roche AH
    Am Heart J; 1977 Nov; 94(5):593-9. PubMed ID: 333889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide].
    Hidaka T; Inoue T; Komoriya K; Hayashi Y; Inomata N
    Nihon Yakurigaku Zasshi; 2000 May; 115(5):295-308. PubMed ID: 10872181
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myocardial and ventricular mechanics as influenced by disopyramide.
    Vogt M; Mohrmann J; Ott B; Jacob R
    Arzneimittelforschung; 1986 Jul; 36(7):1049-53. PubMed ID: 3768071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Influence of canrenoate potassium (aldactone pro injections) on hemodynamics and myocardial ischemia in experimental myocardial infarct].
    Kötter V; Leitner Ev; Arbeiter G; Cordes R; Schröder R
    Z Kardiol; 1975 Jul; 64(7):672-86. PubMed ID: 1163092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hemodynamic dose-response effects of flecainide in acute myocardial infarction with and without left ventricular decompensation.
    Jackson N; Verma SP; Frais MA; Silke B; Hafizullah M; Reynolds G; Taylor SH
    Clin Pharmacol Ther; 1985 Jun; 37(6):619-24. PubMed ID: 3891187
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemodynamics of intravenous disopyramide.
    Sutton R
    J Int Med Res; 1976; 4(1 Suppl):46-8. PubMed ID: 1026528
    [No Abstract]   [Full Text] [Related]  

  • 55. [Hemodynamic effects of disopyramide and procainamide in open-chest animals].
    Binetti G; Branzi A; Malini PL; Specchia S; Magelli C; Zannoli R; Magnani B
    G Ital Cardiol; 1978; 8(12):1314-9. PubMed ID: 738572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disopyramide and lignocaine. A comparison of cardiac effects using echocardiography.
    Martin MA; Bax ND; Tucker GT; Ward JW
    Br J Clin Pharmacol; 1980 Sep; 10(3):237-44. PubMed ID: 7437240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of disopyramide phosphate on early post-coronary artery ligation dysrhythmias and on epicardial ST-segment elevation in anaesthetized dogs.
    Marshall RJ; Parratt JR
    Br J Pharmacol; 1979 Jun; 66(2):241-50. PubMed ID: 465877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
    Komori S; Sawanobori T; Tamura K; Kane KA; Parratt JR
    Jpn J Pharmacol; 1994 Jul; 65(3):193-200. PubMed ID: 7799519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disopyramide: serum level and arrhythmia conversion.
    Niarchos AP
    Am Heart J; 1976 Jul; 92(1):57-64. PubMed ID: 785988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Oral longterm therapy with disopyramide phosphate in patients with atrial and ventricular arrhythmias (author's transl)].
    Stauch M; Grewe N
    MMW Munch Med Wochenschr; 1977 Dec; 119(48):1563-6. PubMed ID: 74799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.